The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. (Q54579373)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. |
scientific article |
Statements
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. (English)
Christoph Bode
1 reference
Dennis Wolf
Ingo Hilgendorf
Sara Eisele
Imke Remer
Jochen Schmitz
Katharina Zeschky
Christian Colberg
Peter Stachon
Florian Willecke
Maike Buchner
Katja Zirlik
Alexandra Ortiz-Rodriguez
Andrey Lozhkin
Natalie Hoppe
Constantin von zur Muhlen
Axel zur Hausen
Andreas Zirlik
23 June 2011
31
9
1991-1999